immunotherapy trail

A new treatment for type 2 diabetes has been approved by the Food and Drug Administration (FDA) which could improve the blood glucose levels of those with the condition.

Adlyxin (lixisenatide) is a once-a-day injection which works to improve glycemic control. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, produced by Sanofi-Aventis.

However, it is key to remember that, as with all type 2 diabetes treatment, that it should be taken in tandem with a healthy diet and exercise, in order to help control blood glucose levels.

Doctor Mary Thanh Hair Park, the deputy director of the Office of Drug Evaluation II at the FDA’s Center for Drug Evaluation and Research said: “The FDA continues to support the development of new drug therapies for diabetes management… Adlyxin will add to the available treatment options to control blood sugar levels for those with type 2.”

The drug has been put through 10 safety trials. 5,400 patients with type 2 diabetes participated in these trials, and in addition, more than 6,000 people with type 2 diabetes and a risk of atherosclerotic cardiovascular disease were treated with either Adlyxin or a placebo, and there was no difference in cardiovascular outcomes.

As with many medications, it was found to cause some side effects, including dizziness and nausea. Furthermore, it cannot be used to treat type 1 diabetes, nor those with high levels of ketones in their blood.

Two further tests need to be carried out before the FDA can fully clear the drug, but so far, Adlyxin seems likely to find its way to the market.